BioXcel Therapeutics Short Long Term Debt Total Over Time
| BTAI Stock | USD 2.74 0.01 0.37% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out BioXcel Therapeutics Performance and BioXcel Therapeutics Correlation. BioXcel |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BioXcel Therapeutics. If investors know BioXcel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BioXcel Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (32.64) | Revenue Per Share | Quarterly Revenue Growth (0.37) | Return On Assets | Return On Equity |
The market value of BioXcel Therapeutics is measured differently than its book value, which is the value of BioXcel that is recorded on the company's balance sheet. Investors also form their own opinion of BioXcel Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is BioXcel Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BioXcel Therapeutics' market value can be influenced by many factors that don't directly affect BioXcel Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BioXcel Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if BioXcel Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioXcel Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Short Long Term Debt Total Analysis
Compare BioXcel Therapeutics and related stocks such as Terns Pharmaceuticals, Amylyx Pharmaceuticals, and Acumen Pharmaceuticals Short Long Term Debt Total Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TERN | 12.9 M | 12.9 M | 12.9 M | 12.9 M | 12.9 M | 12.9 M | 12.9 M | 12.9 M | 12.9 M | 12.9 M | 12.9 M | 1.2 M | 1.2 M | 603 K | 542.7 K | 515.6 K |
| ABOS | 201 K | 201 K | 201 K | 201 K | 201 K | 201 K | 201 K | 201 K | 201 K | 201 K | 201 K | 201 K | 105 K | 28.5 M | 32.8 M | 34.4 M |
| INZY | 1.3 M | 1.3 M | 1.3 M | 1.3 M | 1.3 M | 1.3 M | 1.3 M | 1.3 M | 1.3 M | 1.3 M | 1.3 M | 3.4 M | 6.8 M | 46.6 M | 53.6 M | 56.3 M |
| XFOR | 7.2 M | 7.2 M | 7.2 M | 7.2 M | 7.2 M | 7.2 M | 15.3 M | 12.2 M | 9.6 M | 22.9 M | 38.4 M | 39.8 M | 38.4 M | 58.3 M | 67 M | 70.4 M |
| DAWN | 402 K | 402 K | 402 K | 402 K | 402 K | 402 K | 402 K | 402 K | 402 K | 402 K | 402 K | 220 K | 813 K | 408 K | 2.6 M | 2.7 M |
| APLS | 52.8 M | 52.8 M | 52.8 M | 52.8 M | 52.8 M | 52.8 M | 52.8 M | 52.8 M | 27 M | 157 M | 377.7 M | 210.2 M | 112.7 M | 110.9 M | 469.8 M | 493.3 M |
| EXEL | 13.3 M | 181.5 M | 335.7 M | 347.2 M | 361.7 M | 799.4 M | 189.1 M | 72 M | 56.9 M | 50.7 M | 49.1 M | 51.3 M | 190.2 M | 189.9 M | 190.8 M | 180.8 M |
| TGTX | 800 K | 4.9 M | 3.2 M | 742.3 K | 275.2 K | 211.5 K | 68.9 K | 127.6 K | 67 K | 40.8 M | 42 M | 79 M | 83.1 M | 110.8 M | 253.7 M | 266.4 M |
| VKTX | 42.8 K | 42.8 K | 42.8 K | 278.7 K | 1.6 M | 2.2 M | 3.3 M | 3.5 M | 662 K | 662 K | 359 K | 29 K | 1.6 M | 1.3 M | 1.1 M | 1.1 M |
| MDGL | 1.7 M | 16.6 M | 12.4 M | 23.4 M | 13.9 M | 4.7 M | 676 K | 676 K | 676 K | 676 K | 786 K | 797 K | 49.9 M | 117.2 M | 983 K | 933.9 K |
| ELEV | 29.4 M | 29.4 M | 29.4 M | 29.4 M | 29.4 M | 29.4 M | 29.4 M | 29.4 M | 29.4 M | 29.4 M | 29.4 M | 29.4 M | 29.4 M | 30.1 M | 34.7 M | 32.8 M |
| MREO | 2.8 M | 2.8 M | 2.8 M | 2.8 M | 2.8 M | 2.8 M | 3.1 M | 20.8 M | 21.5 M | 32.4 M | 17.9 M | 16.8 M | 12.8 M | 6 M | 6.8 M | 6.5 M |
| HEPA | 10.4 K | 10.4 K | 10.4 K | 10.4 K | 10.4 K | 10.4 K | 10.4 K | 1.4 M | 1.4 M | 807.4 K | 752.2 K | 317 K | 53.6 K | 209 K | 188.1 K | 338.6 K |
BioXcel Therapeutics and related stocks such as Terns Pharmaceuticals, Amylyx Pharmaceuticals, and Acumen Pharmaceuticals Short Long Term Debt Total description
My Equities
My Current Equities and Potential Positions
| BioXcel Therapeutics | BTAI |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Connecticut; U.S.A |
| Exchange | NASDAQ Exchange |
USD 2.64
Check out BioXcel Therapeutics Performance and BioXcel Therapeutics Correlation. For more detail on how to invest in BioXcel Stock please use our How to Invest in BioXcel Therapeutics guide.You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
BioXcel Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.